Equities analysts predict that Onconova Therapeutics Inc (NASDAQ:ONTX) will announce ($0.66) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Onconova Therapeutics’ earnings, with estimates ranging from ($0.73) to ($0.59). Onconova Therapeutics posted earnings of ($0.29) per share in the same quarter last year, which suggests a negative year over year growth rate of 127.6%. The company is scheduled to issue its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Onconova Therapeutics will report full year earnings of ($3.03) per share for the current year, with EPS estimates ranging from ($3.30) to ($2.75). For the next financial year, analysts anticipate that the business will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.02) to ($1.67). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Onconova Therapeutics.

Onconova Therapeutics (NASDAQ:ONTX) last issued its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.43. The company had revenue of $0.32 million during the quarter, compared to the consensus estimate of $0.25 million.

ONTX has been the subject of a number of recent analyst reports. HC Wainwright started coverage on Onconova Therapeutics in a research note on Monday, October 9th. They issued a “buy” rating and a $6.00 price objective for the company. Dawson James restated a “buy” rating on shares of Onconova Therapeutics in a research report on Tuesday, July 25th. ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Maxim Group set a $6.00 price objective on Onconova Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $7.33.

TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/28/0-66-earnings-per-share-expected-for-onconova-therapeutics-inc-ontx-this-quarter.html.

Onconova Therapeutics (NASDAQ:ONTX) traded up 0.45% during mid-day trading on Friday, hitting $2.25. The company’s stock had a trading volume of 119,568 shares. The company’s 50 day moving average is $2.00 and its 200-day moving average is $2.02. The stock’s market cap is $22.16 million. Onconova Therapeutics has a 52-week low of $1.46 and a 52-week high of $3.88.

Several institutional investors have recently bought and sold shares of the company. Sabby Management LLC raised its stake in Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after acquiring an additional 399,640 shares during the last quarter. Tyndall Capital Partners L P raised its stake in shares of Onconova Therapeutics by 91.4% during the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after buying an additional 476,190 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Onconova Therapeutics by 58.4% during the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 32,418 shares during the last quarter. 26.81% of the stock is owned by hedge funds and other institutional investors.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.